> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Editas Cuts Loss To $23.4 Million As Cholesterol Therapy Heads Toward Patient Testing
- URL: https://www.bullished.co/editas-cuts-loss-to-23-4-million-as-cholesterol-therapy-heads-toward-patient-testing-7c159e6d/
- Published: 2026-11-09T12:26:55.000Z
- Updated: 2026-11-09T12:26:55.000Z
- Description: Partner milestones lifted revenue, while Editas expects its cash to fund operations beyond planned 2027 clinical results.
- Author: Matteo Parrino
- Tags: SEC Filings, EDIT, Industry: Healthcare

[Editas Medicine](https://www.bullished.co/tag/edit/), which develops CRISPR gene-editing medicines, narrowed its third-quarter loss to [$23.4 million](https://www.sec.gov/Archives/edgar/data/0001650664/000165066426000100/edit-20261109.htm?ref=bullished.co) from $25.1 million a year earlier, according to results accompanying its Monday SEC filing. The company also cleared Australian ethics and regulatory steps for its experimental cholesterol therapy, EDIT-401, and expects funding to last beyond the trial’s planned 2027 results.

## Partner Revenue Outpaces Higher Costs

Collaboration and research revenue rose to [$10.4 million](https://www.sec.gov/Archives/edgar/data/0001650664/000165066426000100/editasmedicinepressrelease.htm?ref=bullished.co), compared with $7.5 million in the year-earlier quarter. Editas attributed most of the increase to clinical milestones reached by a partner.

The unaudited loss per share was $0.15, versus $0.28 a year earlier. Weighted-average shares outstanding were 153,604,267, compared with 90,090,397, so the per-share comparison also spans a larger share base.

Research and development costs reached $21.2 million from $19.8 million. Higher licensing fees and spending on EDIT-401 were partly offset by lower employee and outside research costs. Administrative spending increased to $13.5 million from $12.3 million, chiefly because of legal fees for defending intellectual property.

Cash, cash equivalents and marketable securities stood at $190.2 million on September 30, compared with $146.6 million at December 31, 2025\. Editas expects those resources to cover operating costs and capital spending into the second half of 2028.

## EDIT-401 Moves Toward Human Testing

Australian ethics approval and completion of the regulatory notification process permit Editas to [start the Strive](https://www.sec.gov/Archives/edgar/data/0001650664/000165066426000100/editasmedicinepressrelease.htm?ref=bullished.co) early-stage trial. Participants will have heterozygous familial hypercholesterolemia, an inherited disorder that raises LDL cholesterol and increases the risk of cardiovascular disease.

EDIT-401 is designed as a one-time treatment that edits the LDLR gene to increase production of its protein and lower LDL cholesterol. The program fits Editas’ focus on medicines that edit DNA inside the patient’s body.

Animal evidence remains distinct from patient results. At the American Heart Association’s November scientific sessions, Editas presented an ongoing non-human-primate study in which LDL cholesterol reductions of at least 90% persisted over 10 months. Mean reductions of about 90% in the cholesterol-related markers Lp(a) and ApoB persisted over three months.

The company reported temporary liver-test elevations, no tissue abnormalities and no evidence of genetic damage in relevant primary human cells. Those findings are preclinical.

Gilmore O’Neill, president and CEO of Editas Medicine, said, “we look forward to [executing on](https://www.sec.gov/Archives/edgar/data/0001650664/000165066426000100/editasmedicinepressrelease.htm?ref=bullished.co) the Strive study and generating additional data in 2027.”

## Licensing Supports The Clinical Push

Editas earns revenue through CRISPR patent licenses and drug-development collaborations. Its Bristol Myers Squibb collaboration triggered a milestone payment when a second clinical-trial application was accepted.

Bristol Myers Squibb will test BMS-986527, a donor-derived, gene-edited T-cell therapy, in an early-stage study of clear cell renal cell carcinoma, the most common kidney cancer. Editas supplied the Cas12a editing technology used to engineer the cells.

The company appointed Dan Ory as chief medical officer in September to oversee clinical strategy and operations for EDIT-401 and the wider pipeline. His experience spans more than 25 years in biotechnology, cardiovascular medicine and genetic medicines.

Editas expects patient dosing to begin this year, initial safety and tolerability findings in the first quarter of 2027, and Part 1 safety and efficacy results in the second half of 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Editas Medicine, Inc. (EDIT)](https://www.sec.gov/Archives/edgar/data/0001650664/000165066426000100/edit-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit editasmedicinepressrelease.htm — Editas Medicine, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001650664/000165066426000100/editasmedicinepressrelease.htm?ref=bullished.co) — SEC EDGAR
- [Editas Medicine Announces Third Quarter 2026 Results and](https://www.globenewswire.com/news-release/2026/11/09/3398224/0/en/editas-medicine-announces-third-quarter-2026-results-and-business-updates.html?ref=bullished.co) — globenewswire.com

### More on Editas Medicine

- [BlackRock Now Holds 7.8% Of Editas Medicine, A Stake Of 11.9 Million Shares](https://www.bullished.co/blackrock-now-holds-7-8-of-editas-medicine-a-stake-of-11-9-million-shares-08539632/)
- [Editas Clears Australian Hurdle To Dose First Patients With Cholesterol Gene Editor EDIT-401](https://www.bullished.co/editas-clears-australian-hurdle-to-dose-first-patients-with-cholesterol-gene-editor-edit-c6e82b44/)

[All Editas Medicine (EDIT) coverage →](https://www.bullished.co/tag/edit/)